Your browser doesn't support javascript.
loading
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Samur, Mehmet Kemal; Roncador, Marco; Aktas Samur, Anil; Fulciniti, Mariateresa; Bazarbachi, Abdul Hamid; Szalat, Raphael; Shammas, Masood A; Sperling, Adam S; Richardson, Paul G; Magrangeas, Florence; Minvielle, Stephane; Perrot, Aurore; Corre, Jill; Moreau, Philippe; Thakurta, Anjan; Parmigiani, Giovanni; Anderson, Kenneth C; Avet-Loiseau, Hervé; Munshi, Nikhil C.
Affiliation
  • Samur MK; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Roncador M; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA.
  • Aktas Samur A; Zurich University Hospital, Zurich, Switzerland.
  • Fulciniti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Bazarbachi AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Szalat R; Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY.
  • Shammas MA; Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, MA.
  • Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Magrangeas F; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Minvielle S; Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), INSERM, French National Centre for Scientific Research (CNRS), Angers University, and Nantes University, Nantes, France.
  • Perrot A; Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), INSERM, French National Centre for Scientific Research (CNRS), Angers University, and Nantes University, Nantes, France.
  • Corre J; University Cancer Center of Toulouse Institut National de la Santé, Toulouse, France.
  • Moreau P; University Cancer Center of Toulouse Institut National de la Santé, Toulouse, France.
  • Thakurta A; Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), INSERM, French National Centre for Scientific Research (CNRS), Angers University, and Nantes University, Nantes, France.
  • Parmigiani G; Bristol Myers Squibb, Summit, NJ.
  • Anderson KC; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Avet-Loiseau H; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA.
  • Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
Blood ; 141(14): 1724-1736, 2023 04 06.
Article in En | MEDLINE | ID: mdl-36603186
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Blood Year: 2023 Type: Article Affiliation country: Morocco
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Blood Year: 2023 Type: Article Affiliation country: Morocco